CAR-T Target Luciferase Reporter Cells
CAR-T Target Luciferase Reporter Cells can be used as a target cancer cell for in vitro killing assay by CD19, CD20, or HER2 CAR-T cells. These luciferase expressing cell lines were derived from parental lines by transduction with lentiviral vector encoding firefly luciferase gene (luc2) under control of EF-1 alpha promoter. These cell lines were established through single cell cloning, and the cells constitutively express high levels of enzymatically active luciferase protein, which can be detected via in vitro and bioluminescence assays. The cells should be maintained in Blasticidin (8 µg/mL) containing medium in routine cell culture. It is recommended to remove Blasticidin prior to and during the experiment procedure when the cells co-cultured with other cell types in vitro.
WIL2-S-Luc2 CRL-8885-LUC2™ has been used as a target cancer cell for in vitro killing assay by CD19 CAR-T cells (tested at ATCC) and is expected to also work for CD20 CAR-T cells. WIL2-S-Luc2 has been verified to express high levels of CD19.
Raji-Luc2 CCL-86-LUC2™ has been used as a target cancer cell for in vitro killing assay by CD19 CAR-T cells (tested at ATCC) and is expected to also work for CD20 CAR-T cells. Raji-Luc2 naturally expresses high levels of CD19 (verified at ATCC).
Daudi-Luc2 CCL-213-LUC2™ has been used as a target cancer cell for in vitro killing assay by CD20 CAR-T cells (tested at ATCC) and is expected to also work for CD19 CAR-T cells. Daudi-Luc2 has been verified to express high levels of CD20.
Farage-Luc2 CRL-2630-LUC2™ has been used as a target cancer cell for in vitro killing assay by CD20 CAR-T cells (tested at ATCC) and is expected to also work for CD19 CAR-T cells. Farage-Luc2 has been verified to express high levels of CD20.
Finally, BT-474-Luc2 HTB-20-LUC2 ™ has been used as a target cancer cell for in vitro killing assay by HER2 CAR-T cells (tested at ATCC). BT-474 naturally expresses high levels of the gene HER2 (verified at ATCC).